文献速递造血干细胞移植与细胞治疗

GvHD预防策略对年轻成人无关供者HSCT无GvHD无复发生存的影响

Impact of graft-versus-host disease prophylaxis strategies on GvHD-free/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.
PubMed 文献 · Br J Haematol · 2025-12-05

该回顾性队列研究基于CIBMTR数据纳入1387例接受无关供者HSCT的年轻成人,比较三种GvHD预防方案的24个月GRFS。倾向性评分匹配后,PTCy组GRFS仍显著高于CNI-MTX/MMF±ATG组,且PTCy独立降低NRM,复发与OS无显著差异。

要点

  • 年轻成人无关供者HSCT中,PTCy方案24个月GRFS达58.9%,显著优于CNI+MTX/MMF的32.2%。
  • 多因素分析显示PTCy独立改善GRFS(HR=0.44),并降低非复发死亡率。
  • 各组间复发率与总生存无显著差异,支持PTCy方案在该人群的应用。

核心结论

  • 在年轻成人无关供者HSCT中,PTCy为基础的预防方案与显著改善的GRFS和降低的NRM相关。
  • 研究结果支持在该人群中使用PTCy方案,并值得前瞻性评估。

研究设计与样本

  • 回顾性分析,使用CIBMTR当代数据集,纳入1387例接受无关供者HSCT的年轻成人患者。
  • 比较三组GvHD预防策略:A组PTCy+CNI+MMF,B组CNI+MTX/MMF,C组CNI+MTX/MMF+ATG。
  • 采用倾向性评分匹配分析调整基线差异。

主要发现

  • 总队列24个月GRFS:A组58.9%(95%CI 53-64),B组32.2%(95%CI 29-36),C组44.2%(95%CI 39-49),p<0.001。
  • 多因素分析中,A组HR=0.44(95%CI 0.35-0.54),C组HR=0.79(95%CI 0.70-0.90),均较B组改善GRFS。
  • 倾向性评分匹配队列24个月GRFS:PTCy组58.2%(95%CI 52-64) vs CNI-MTX/MMF±ATG组32.9%(95%CI 27-39),p<0.001。
  • 匹配队列中PTCy独立关联改善GRFS(HR=0.48,95%CI 0.40-0.60,p<0.001)。
  • PTCy方案降低非复发死亡率,各组间复发与总生存无显著差异。

临床怎么用

  • 对于接受无关供者HSCT的年轻成人,可考虑优先选用PTCy为基础的GvHD预防方案以改善GRFS并降低NRM。

局限性

  • 研究为回顾性分析,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Young adults (YAs) undergoing allogeneic haematopoietic stem cell transplantation (HSCT) represent a unique population with distinct medical and psychosocial needs. Optimizing graft-versus-host disease (GvHD) prophylaxis in this population remains critical to improving outcomes. We performed a retrospective analysis of YAs undergoing unrelated donor HSCT using a contemporary Center for International Blood and Marrow Transplant Research (CIBMTR) dataset. GvHD-free, relapse-free survival (GRFS) at 24 months was evaluated across three GvHD prophylaxis strategies: Group A (post-transplant cyclophosphamide [PTCy] + calcineurin inhibitor [CNI] + mycophenolate mofetil [MMF]), Group B (CNI + methotrexate [MTX]/MMF), and Group C (CNI + MTX/MMF + anti-thymocyte globulin [ATG]). A propensity score-matched (PSM) analysis was conducted to adjust for baseline differences. A total of 1387 YA patients were included. In the total cohort, 24-month GRFS was 58.9% (confidence intervals [95% CI], 53-64) in Group A, 32.2% (95% CI, 29-36) in Group B and 44.2% (95% CI, 39-49) in Group C (p < 0.001). On multivariable analysis (MVA), both Group A (hazard ratio [HR] = 0.44; 95% CI, 0.35-0.54) and Group C (HR = 0.79; 95% CI, 0.70-0.90) showed improved GRFS compared to Group B. In the propensity score-matched cohort, GRFS at 24 months remained higher in the PTCy group (58.2%, 95% CI, 52-64) versus the CNI-MTX/MMF ± ATG group (32.9%, 95% CI, 27-39; p < 0.001), with PTCy independently associated with improved GRFS (HR = 0.48; 95% CI, 0.40-0.60; p < 0.001). PTCy-based prophylaxis also reduced non-relapse mortality (NRM), with no significant differences in relapse or overall survival (OS) between groups. In this large, retrospective analysis, PTCy was associated with significantly improved GRFS and reduced NRM in YAs undergoing unrelated donor HSCT. These findings support the use of PTCy-based regimens in this population and warrant prospective evaluation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Desai N, Rodriguez SR, Al-Shaibani E, et al. Impact of graft-versus-host disease prophylaxis strategies on GvHD-free/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis. Br J Haematol. 2025. PMID: 41346275. doi:10.1111/bjh.70269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。